Abstract
A variant cell line (UV-2237-ADMR) resistant to the anthracycline antibiotic Adriamycin (doxorubicin) was selected in vitro from the murine UV-2237 fibrosarcoma tumor cell line. Resistance to Adriamycin proved to be a stable characteristic of the UV-2237-ADMR line, whether the line was grown in vivo or in vitro. The UV-2237-ADMR line also exhibited increased resistance to N-trifluoroacetyladriamycin-14-valerate, daunorubicin, actinomycin D, amsacrine, mitomycin C, vinblastine, and vincristine but not to bleomycin. Cell-cell hybridization studies showed that the Adriamycin resistance is an incompletely dominant trait. Uptake and efflux studies with [14C]Adriamycin indicated that the resistance exhibited by the UV-2237-ADMR line was due to both reduced uptake of the drug and an increased active efflux.
Footnotes
-
↵1 Research sponsored by the National Cancer Institute, Department of Health and Human Services, under Contract N01-CO-75380 with Litton Bionetics, Inc.
-
↵2 Recipient of a fellowship for advanced professional training from the Italian Labor Department and the European Economic Community. On leave of absence from Istituto di Ricerche Farmacologiche “Mario Negri,” Milan, Italy. To whom requests for reprints should be addressed.
- Received September 13, 1982.
- Accepted February 3, 1983.
- ©1983 American Association for Cancer Research.
Volume 43, Issue 5
